Session 120 - CROI 2011

Home

Session 120-Poster Abstracts
Pharmacokinetics and Drug Interactions of New and Existing Antiretroviral Agents
Monday, 2-4 pm; Hall A

627	TBR-652 Absorption, Distribution, Metabolism, and Excretion Profile in Rats, Dogs, Monkeys, and Humans David Martin*¹, M Kawase², S Asahi², Y Tagawa², T Kondo², A Morohasi², M Nishihara², H Yamasaki², R Ogden¹, and S Palleja¹ ¹Tobira Therapeutics, Inc, Manalapan, NJ, US and ²Takeda Pharmaceutical Co, Ltd, Tokyo, Japan
628	Dose Selection for Phase IIb Studies of GSK2248761, a Next-generation NNRTI, Using PK/PD/VD Model and Trial Simulation Joseph Kim*, MB Wire, and M Lovern GlaxoSmithKline, Research Triangle Park, NC, US
629	Low-dose RTV and the Pharmacokinetics of the Investigational HCV Protease Inhibitor TVR in Healthy Volunteers Varun Garg*¹, X Luo¹, L McNair¹, R van Heeswijk², and R Kauffman¹ ¹Vertex Pharmaceuticals Inc, Cambridge, MA, US and ²Tibotec BVBA, Beerse, Belgium
630	Pharmacokinetic Parameters of Once-daily TMC278 following Administration of EFV in Healthy Volunteers Herta Crauwels*¹, J Vingerhoets¹, R Ryan², J Witek³, and D Anderson³ ¹Tibotec BVBA, Beerse, Belgium; ²Tibotec Inc, Titusville, NJ, US; and ³Tibotec Therapeutics, Titusville, NJ, US
631	Lack of Drug-drug Interaction between the NNRTI GSK2248761 and RAL Joseph Kim*, E Gould, Y Lou, S White, and S Piscitelli GlaxoSmithKline, Research Triangle Park, NC, US
632	Pharmacokinetics of DRV/r and ATV/r Once Daily over 72 Hours following Drug Cessation M Boffito¹, Akil Jackson*¹, A Amara², D Back², S Khoo², C Higgs¹, N Seymour¹, B Gazzard¹, and G Moyle¹ ¹St Stephens Ctr, Chelsea and Westminster Hosp, London, UK and ²Univ of Liverpool, UK
633	Novel Method to Assess Antiretroviral Target Trough Concentrations Using in vitro Susceptibility Data Edward Acosta*¹, K Limoli², L Trinh², N Parkin³, J King¹, J Weidler², I Ofotokun⁴, and C Petropoulos² ¹Univ of Alabama at Birmingham Sch of Med, US; ²Monogram Biosci, Inc, South San Francisco, CA, US; ³Data First Consulting Inc, Menlo Park, CA, US; and ⁴Emory Univ, Atlanta, GA, US
634	Pharmacokinetics of Once-daily RAL/ATV in HIV-1-infected Patients A Jansen¹, A Colbers², A van der Ven², C Richter¹, J Rockstroh³, J-C Wasmuth³, M van Luin¹, and David Burger*² ¹Alysis Zorggroep, Arnhem, The Netherlands; ²Radboud Univ Nijmegen Med Ctr, The Netherlands; and ³Univ of Bonn, Germany
635	Influence of pH on Transcellular Permeability of RAL: Unravelling the Interaction with Antacids and Food Darren Moss*, M Murphy, M Siccardi, S Khoo, D Back, and A Owen Univ of Liverpool, UK
636	MVC 300 mg Once Daily + DRV/RTV 800/100 mg Once Daily Provides MVC Trough Concentrations Comparable to Trough Concentrations in HIV-1 Patients Taking MVC 300 mg Twice Daily + TVD: Implications for Phase 3 Studies Stephen Taylor*^1,2,3, N Dufty^1,3, J Watson^1,3, D White^1,2, G Gilleran¹, S Barrett^1,2, C Robertson^1,2, K Gandhi¹, and E Smit^1,4 ¹Birmingham Heartlands Hosp, UK; ²Univ of Birmingham, UK; ³Royal Ctr for Defence Med, Birmingham, UK; and ⁴Hlth Protection Agency, Birmingham, UK
637	Pharmacokinetic and Pharmacodynamic Activity of the Combined Oral Contraceptives in HIV⁺ Women in Lilongwe, Malawi Gretchen Stuart*¹, A Moses², A Corbett³, G Phiri², W Kumwenda², N Mkandwire², J Chintedze², M Hosseinipour^1,2, F Stanczyk⁴, and A Kashuba³ ¹Univ of North Carolina at Chapel Hill Sch of Med, US; ²UNC Project, Lilongwe, Malawi; ³Univ of North Carolina at Chapel Hill Sch of Pharmacy, US; and ⁴Univ of Southern California, Los Angeles, US